{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:20:27Z","timestamp":1700252427026},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T00:00:00Z","timestamp":1080000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Ophthalmologica Scandinavica"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To compare the efficacy and safety of unoprostone versus brimonidine both given twice daily in ocular hypertensive or primary open\u2010angle glaucoma subjects.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> After a 1\u2010month washout period a baseline diurnal curve was measured every 2\u2003hours from 08\u2003:\u200300\u2003hours (trough) to 20\u2003:\u200300\u2003hours in subjects with a trough intraocular pressure (IOP) and the pressure 24\u2003mmHg. Qualified subjects were randomized to either brimonidine or unoprostone. After 6\u2003weeks of treatment the period 1 diurnal curve was performed. Subjects were then switched to the opposite treatment for 6\u2003weeks and the period 2 diurnal curve was performed.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> A total of 33 subjects were included in this study. In the brimonidine\u2010treated group the trough IOP 20.1\u2003\u00b1\u20032.8\u2003mmHg was reduced from baseline up to 8\u2003hours after dosing. In the unoprostone\u2010treated group the trough IOP was 19.5\u2003\u00b1\u20033.0\u2003mmHg, which was statistically equal to that of brimonidine (p\u2003<jats:italic>=<\/jats:italic>\u20030.21), was reduced from baseline for 12\u2003hours after dosing. Brimonidine decreased the IOP statistically more than unoprostone at 10\u2003:\u200300 and 12\u2003:\u200300 hours (p\u2003<jats:italic>&lt;<\/jats:italic>\u20030.0001 and p\u2003=\u20030.02, respectively), while unoprostone reduced the IOP more than brimonidine at 18\u2003:\u200300 and 20\u2003:\u200300\u2003hours (p\u2003<jats:italic>=<\/jats:italic>\u20030.002 and p\u2003=\u20030.05, respectively). Safety levels were similar between groups, but unoprostone caused more ocular stinging than brimonidine (p\u2003<jats:italic>=<\/jats:italic>\u20030.008).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> This study suggests that twice daily brimonidine demonstrates a statistically greater peak reduction in IOP than unoprostone. However, unoprostone, but not brimonidine, decreased IOP over the complete 12\u2010hour daytime dosing cycle.<\/jats:p>","DOI":"10.1111\/j.1600-0420.2004.00225.x","type":"journal-article","created":{"date-parts":[[2004,12,19]],"date-time":"2004-12-19T05:35:57Z","timestamp":1103434557000},"page":"161-165","source":"Crossref","is-referenced-by-count":4,"title":["The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%"],"prefix":"10.1111","volume":"82","author":[{"given":"William C.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas G.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00943-0"},{"key":"e_1_2_6_3_1","first-page":"205","volume-title":"Essentials of statistics","author":"Book SA","year":"1978"},{"key":"e_1_2_6_4_1","first-page":"19","article-title":"Adrenergic agonist medications: basic mechanisms","volume":"4","author":"Derick RJ","year":"1995","journal-title":"J Glaucoma"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1987.tb07052.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1985.01050120030015"},{"key":"e_1_2_6_7_1","first-page":"554","article-title":"Efficacy and safety of unoprostone, dorzolamide, and brimonidine in adjunctive therapy to timolol in patients with primary open\u2010angle glaucoma and ocular hypertension","volume":"42","author":"Hommer AB","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00286-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00834-0"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1998.14.129"},{"key":"e_1_2_6_11_1","first-page":"164","volume-title":"Applied Linear Regression Model","author":"Neter J","year":"1989"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01337-X"},{"key":"e_1_2_6_13_1","first-page":"156","article-title":"Effects of topical application of UF\u201021, a novel prostaglandin\u2010related compound, on aqueous humour dynamics in normal human eyes","volume":"35","author":"Sakurai M","year":"1991","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(96)82029-7"},{"key":"e_1_2_6_15_1","article-title":"Brimonidine 0.2% versus unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open\u2010angle glaucoma or occular hypertension","author":"Sharpe ED","year":"2004","journal-title":"Eye"},{"key":"e_1_2_6_16_1","first-page":"63","volume-title":"Non\u2010parametric Statistics for the Behavioural Sciences","author":"Siegel S","year":"1956"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00902-8"},{"key":"e_1_2_6_18_1","first-page":"557","article-title":"Comparison of the IOP\u2010lowering efficacy and safety of the docosanoid unoprostone isopropyl 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open\u2010angle glaucoma or ocular hypertension","volume":"42","author":"Stewart WC","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00495-4"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00076-8"},{"key":"e_1_2_6_21_1","first-page":"1099","article-title":"The impact of entry criteria on the baseline IOP in glaucoma studies: a meta\u2010analysis","volume":"37","author":"Vogel R","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Acta Ophthalmologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0420.2004.00225.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0420.2004.00225.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:11:24Z","timestamp":1697184684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0420.2004.00225.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,23]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1111\/j.1600-0420.2004.00225.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0420.2004.00225.x","archive":["Portico"],"relation":{},"ISSN":["1395-3907","1600-0420"],"issn-type":[{"value":"1395-3907","type":"print"},{"value":"1600-0420","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,23]]}}}